SCHEMBL2241648

SCHEMBL2241648

COc1cc(NC2=C(Cl)C(=O)c3ccccc3C2=O)ccc1S(=O)(=O)Nc1ccccc1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
MAPK1 P28482 4/20 0.50
NPC1 O15118 4/20 0.49
MAPT P10636 4/20 0.49
HTT P42858 4/20 0.49
RAB9A P51151 4/20 0.49
MITF O75030 2/20 0.49
P2RY4 P51582 3/20 0.48
GRM4 Q14833 1/20 0.47
CDC25A P30304 1/20 0.46
CDC25B P30305 1/20 0.46
PGAM1 P18669 1/20 0.45
ALDH1A1 P00352 3/20 0.44
HPGD P15428 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
TCF4 P15884 1/20 0.44
ALOX15 P16050 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2243847 0.87 HTT (0.61) MEN1KMT2AMAPK1NPC1MAPT
SCHEMBL2244992 0.85 CYP19A1 (0.55) MEN1KMT2AMAPK1NPC1MAPT
SCHEMBL2237410 0.84 MEN1 (0.55) MEN1KMT2AMAPK1NPC1MAPT
SCHEMBL15906856 0.84 MAPT (0.61) MEN1KMT2AMAPK1NPC1MAPT
SCHEMBL12352059 0.81 MAPT (0.49) MEN1KMT2AMAPK1NPC1MAPT
SCHEMBL2242640 0.81 ALDH1A1 (0.62) MEN1KMT2AMAPK1NPC1MAPT
SCHEMBL12283197 0.79 MAPT (0.60) MEN1KMT2AMAPK1NPC1MAPT
SCHEMBL2244155 0.78 PSMB1 (0.61) MEN1KMT2AMAPK1NPC1MAPT
SCHEMBL15906855 0.76 MAPT (0.60) MEN1KMT2AMAPK1NPC1MAPT
SCHEMBL5806361 0.75 MAPT (0.64) MEN1KMT2AMAPK1NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673910-B2 Proteasome inhibitors for selectively inducing apoptosis in cancer cells H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) 2014-03-18 US disclosed
US-8673910-B2 Proteasome inhibitors for selectively inducing apoptosis in cancer cells H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) 2014-03-18 US disclosed
US-20110201609-A1 PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) 2011-08-18 US disclosed
US-20110201609-A1 PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) 2011-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201609-A1 PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS PSMB7, PSMD7, PSMB6 MEN1 4575/4885KMT2A 2094/4885MAPK1 3066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.